Genetics of HDL regulation in humans

Current Opinion in Lipidology

Volumn 14, Issue 3, 2003, Pages 273-279

  Miller, Michael ^a   Rhyne, Jeffrey ^b   Hamlette, Steven ^b   Birnbaum, Josh ^b   Rodriguez, Anabelle ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CELL NUCLEUS RECEPTOR; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL MODEL; CHOLESTEROL TRANSPORT; CORRELATION ANALYSIS; DOWN REGULATION; GENE CONTROL; GENETIC STRAIN; GENETIC VARIABILITY; GENETICS; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MOLECULAR DYNAMICS; MONOGENIC DISORDER; NONHUMAN; PATHOLOGY; PEROXISOME; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANIMALS; ANTIGENS, CD36; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DOWN-REGULATION; GLYCOPROTEINS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN LIPASE; LIVER; MEMBRANE PROTEINS; MUTATION; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS B; UP-REGULATION;

ANIMALIA;

EID: 0037832578     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200306000-00007     Document Type: Review

References (75)

1. Wang X, Paigen B. Quantitative trait loci and candidate genes regulating HDL cholesterol: a murine chromosome map. Arterioscler Thromb Vasc Biol 2002; 22:1390-1401. A useful summarization of the 27 mouse and 22 human quantitative trait loci for HDL-cholesterol and their comparable homologous regions.
2. Hobbs HH, Rader DJ. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest 1999; 104:1015-1017.
3. Marcil M, Yu L, Krimbou L, et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol 1999; 19:159-169.
4. Wellington CL, Yang YZ, Zhou S, et al. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. J Lipid Res 2002; 43:1939-1949. ABCA1 expression was assessed in human fibroblasts harvested from subjects with and without truncated mutations. Truncated mutations blunted protein expression of the full-length ABCA1 allele and suppressed upregulation by oxysterols.
5. Kakko S, Kelloniemi J, von Rohr P, et al. ATP-binding cassette transporter A1 locus is not a major determinant of HDL-cholesterol levels in a population at high risk for coronary heart disease. Atherosclerosis 2003; 166:285-290. Subjects with low HDL-cholesterol and premature CHD (n = 35) were screened for ABCA1 mutations and family studies evaluated whether the ABCA1 locus segregated with low HDL. In addition, the prevalence of common ABCA1 polymorphisms was studied in a Finnish sample (n = 515). No linkage was identified between ABCA1 and HDL-cholesterol and one of the five mutations screened for were found in this high-risk group. None of the ABCA1 polymorphisms was significantly associated with HDL.
6. Mott S, Yu L, Marcil M, et al. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis 2000; 152:457-468.
7. Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 2001; 42:1717-1726.
8. Hong SH, Riley W, Rhyne J, et al. Lack of association between increased carotid intima-media thickening and decreased HDL-cholesterol in a family with a novel ABCA1 variant, G2265T. Clin Chem 2002; 48:2066-2070. Previous data have suggested that ABCA1 variants causing low HDL is also associated with increased carotid intima-media thickness. In the present study, carotid intima medial thickness was not increased compared to age controlled subjects despite low HDL levels caused by a novel ABCA1 variant.
9. Ho Hong S, Rhyne J, Zeller K, Miller M. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim Biophys Acta 2002; 21:60-64. Two novel mutations in ABCA1 (D1099Y, F2009F) were identified in a family from Kansas. The proband died of complications of cerebral amyloid angiopathy. Despite low HDL, there was no history of premature CHD.
10. Wollmer MA, Streffer JR, Lutjohann D, et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 2003; 24:421-426. Carriers of R219K in ABCA1 were found to have reduced TC (33%) in cerebrospinal fluid and delayed onset of Alzheimer's disease. In contrast, no association was found in carriers of another variant (R1587K). The authors speculate that variability in ABCA1 may impact on the pathogenesis of Alzheimer's disease.
11. Fu X, Menke JG, Chen Y, et al. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001; 276:38378-38387.
12. Sparrow CP, Baffic J, Lam MH, et al. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem 2002; 277:10021-10027. Previous studies have demonstrated that in response to cholesterol loading, oxysterols stimulate the nuclear receptors LXR and LXR and upregulate ABCA1 expression. Using a synthetic agonist for LXR, acetyl-podocarpic acid was found to be significantly more potent in stimulating cholesterol and phospholipid efflux than other LXR agonists (e.g. 22-hydroxycholesterol) and may represent a novel agent for the treatment of CHD.
13. Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterel receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14:2819-2830.
14. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7:53-58.
15. Schaefer EJ. Familial lipoprotein disorders and premature coronary artery disease. Med Clin North Am 1994; 78:21-39.
16. Yokota H, Hashimoto Y, Okubo S, et al. Apolipoprotein A-l deficiency with accumulated risk for CHD but no symptoms of CHD. Atherosclerosis 2002; 162:399-407. This paper describes a 69-year-old woman with apoA-I deficiency resulting from a homozygous base-pair deletion (codon 184) and predicted protein truncation at amino acid 199. Despite markedly reduced HDL (<0.18 mmol/l) and mild elevation in apo B (119 mg/dl) there was no history of symptomatic CHD.
17. Miller M, Aiello D, Pritchard H, et al. Apolipoprotein A-l(Zavalla) (Leu159→Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:1242-1247.
18. Wang WQ, Moses AS, Francis GA. Cholesterol mobilization by free and lipid-bound apoAl(Milano) and apoAl(Milano)-apoAll heterodimers. Biochemistry 2001; 40:3666-3673.
19. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-l(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103:1949-1954.
20. Paris.
21. Staels B, Auwerx J. Regulation of apo A-l gene expression by fibrates. Atherosclerosis 1998; 137:S19-S23.
22. Hargrove GM, Junco A, Wong NC. Hormonal regulation of apolipoprotein Al. J Mol Endocrinol 1999; 22:103-111.
23. Jeenah M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein Al gene is associated with elevated serum apolipoprotein Al and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990; 7:233-241.
24. Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-l gene promoter region: association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest 1992; 89:1796-1800.
25. Mata P, Lopez-Miranda J, Pooovi M, et al. Human apolipoprotein A-l gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998; 137:367-376.
26. Marin C, Lopez-Miranda J, Gomez P, et al. Effects of the human apolipoprotein A-l promoter G-A mutation on postprandial lipoprotein metabolism. Am J Clin Nutr 2002; 76:319-325.
27. Kuivenhoven JA, Pritchard H, Hill J, et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997; 38:191-205.
28. Kasid A, Rhyne J, Zeller K, et al. A novel TC deletion resulting in Pro(260)→Stop in the human LCAT gene is associated with a dominant effect on HDL-cholesterol. Atherosclerosis 2001; 156:127-132.
29. Winder AF, Owen JS, Pritchard PH, et al. A first British case of fish-eye disease presenting at age 75 years: a double heterozygote for defined and new mutations affecting LCAT structure and expression. J Clin Pathol 1999; 52:228-230.
30. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34:1255-1274.
31. Inazu A, Koizumi J, Mabuchi H. Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol 2000; 11:389-396.
32. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
33. Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterel levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998; 27:659-667.
34. Yamashita S, Sakai N, Hirano K, et al. Roles of plasma lipid transfer proteins in reverse cholesterol transport. Front Biosci 2001; 6:D366-D387.
35. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipopreteins. Nature 1989; 342:448-451.
36. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
37. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160-167. A review article regarding CETP in animals and humans, and its confounding role in atherosclerosis.
38. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159-2165. A human clinical trial that showed by using the CETP inhibitor, JTT-705, at high doses (900 mg) HDL-cholesterol increased 34% and LDL-cholesterol decreased 7% and was without major side effects. No clinical endpoints were tested.
39. Lambert G, Amar MJA, Martin P, et al. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. J Lipid Res 2000; 41:667-672.
40. Cai SJ, Wong DM, Chen SH, Chan L. Structure of the human hepatic lipase gene. Biochemistry 1989; 28:8966-8971.
41. Ameis D, Stahnke G, Kobayashi J, et al. Isolation and characterization of the human hepatic lipase gene. J Biol Chem 1990; 265:6552-6555.
42. Deeb SS, Peng R. The C-514 T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000; 41:155-158.
43. Vega GL, Clark LT, Tang A, et al. Hepatic lipase activity is lower in African American men than in white American men: effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res 1998; 39:228-232.
44. Nie L, Niu S, Vega GL, et al. Three polymorphisms associated with low hepatic lipase activity are common in African Americans. J Lipid Res 1998; 39:1900-1903.
45. deLemos AS, Wolfe ML, Long CJ, et al. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation. 2002; 106:1321-1326. This is the first study to assess the endothelial lipase gene for molecular variants in humans. Many polymorphic sites were identified with the focus on six potentially physiologic variants (two in promoter and four in coding regions). Several of these variants were identified with higher frequency in blacks and hyperalpha whites and may contribute to the high HDL phanotype.
46. Cohen JC. Endothelial lipase: direct evidence for a role in HDL metabolism. J Clin Invest 2003; 111:318-321.
47. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271:518-520.
48. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001; 108:793-797.
49. Rigotti A, Edelman ER, Seifert P, et al. Regulation by adrenocorticotrophic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem 1996; 271:33545-33549.
50. Landschulz KT, Pathak RK, Rigotti A, et al. Regulation of scavenger receptor, class B, type I, a high-density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996; 98:984-995.
51. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002; 296:1051-1057. A study that examined the effects of testosterone on SR-BI expression in cultured hepatocytes and macrophages. Results add testosterone to the list of hormones that can affect SR-BI expression.
52. Azhar S, Nomoto A, Leers-Sucheta S, Reaven E. Simultaneous induction of an HDL receptor protein (SR-BI) and the selective uptake of HDL-cholesteryl esters in a physiologically relevant steroidogenic cell model. J Lipid Res 1998; 39:1616-1628.
53. Chinett G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101:2411-2417.
54. Spady DK, Kearney DM, Hobbs HH. Polyunsaturated fatty acids up-regulate hepatic scavenger receptor BI (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. J Lipid Res 1999; 40:1384-1394.
55. Cao G, Garcia CK, Wyne KL, et al. Structure and localization of the human gene encoding SR-BI/CLA-1. J Biol Chem 1997; 272:33068-33076.
56. Hirano K, Yamashita S, Nakagawa Y, et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999; 85:108-116.
57. Rodriguez A, Wee S-B. The HDL receptor protein, SR-BI/CIA1, does not mediate cholesterol efflux from human macrophage foam cells. Circ Suppl 1999; 100:I-538.
58. Acton S, Osgood D, Donoghue M, et al. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler Thromb Vasc Biol 1999; 19:1734-1743.
59. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336-345.
60. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999; 22:352-355.
61. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-351.
62. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106:1263-1270.
63. Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341-1346.
64. Huang W, Moriyama K, Koga T, et al. Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease. Biochim Biophys Acta 2001; 1537:71-78.
65. Brousseau ME, Schaefer EJ, Dupuis J, et al. Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds. J Lipid Res 2000; 41:433-441.
66. Remaley AT, Rust S, Rosier M, et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci U S A 1999; 96:12685-12690.
67. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Ciin Invest 1999; 104:R25-R31.
68. Clee SM, Zwinderman AH, Engert JC, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001; 103:1198-1205.
69. Bertolini S, Pisciotta L, Seri M, et al. A point mutation in ABC1 gene in a patient with severe premature coronary heart disease and mild clinical phenotype of Tangier disease. Atherosclerosis 2001; 154:599-605.
70. Wang J, Burnett JR, Near S, et al. Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterioscler Thromb Vasc Biol 2000; 20:1983-1989.
71. Lapicka-Bodzioch K, Bodzioch M, Krull M, et al. Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. Biochim Biophys Acta 2001; 1537:42-48.
72. Hong SH, Rhyne J, Zeller K, Miller M. ABCA1 (Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis 2002; 164:245-250. This study extends recent data that a single defective allele in ABCA1 may be associated with reduced HDL-cholesterol and FHA.
73. Altilia S, Pisciotta L, Garuti R, et al. Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G > C mutation in ABCA1 gene. J Lipid Res 2003; 44:254-264. This work describes two point mutations in a Tangier disease patient, G > C in intron 2 (IVS2 +5G/C), and 1239 C/T (R282X). The R282X mutation predicts a truncated protein, whereas the splicing mutation was found to disrupt ABCA1 pre-messenger RNA splicing in fibroblasts, leading to abnormal messenger RNAs. ABCA1 minigenes were constructed to examine in-vitro effects.
74. Ishii J, Nagano M, Kujiraoka T, et al. Clinical variant of Tangier disease in Japan: mutation of the ABCA1 gene in hypoalphalipoproteinemia with corneal lipidosis. J Hum Genet 2002; 47:366-369. The authors present a Tangier disease patient with a novel homozygous ABCA1 mutation (R1680W). The clinical manifestations include corneal opacities, premature coronary artery disease, as well as an almost complete absence of HDL-cholesterol.
75. Nishida Y, Hirano K, Tsukamoto K, et al. Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency. Biochem Biophys Res Commun 2002; 290:713-721. Three ABCA1 mutations (G1158A/A255T; C5946T/R1851X; A5226G/N1611D) associated with familial high-density lipoprotein deficiency were examined. While cholesterol efflux was decreased in all fibrobtast lines, abnormalities and dysfunction of ABCA1 occurred at different regulatory levels. In fibroblasts from the A255T patient, the immunoreactive mass of ABCA1 was not detected. In R1851X and N1611D fibroblasts, messenger RNA was shown to be normal. However, R1851X was observed to produce markedly reduced amount of mutant protein and although expression of N1611D ABCA1 protein was normal, cholesterol efflux from the cells was markedly reduced.